Go Ad-Free
    My Alerts
    Moneycontrol
    Moneycontrol PRO
    HomeNewsGlenmarkpharma

    Stock analysis is used by traders to make buy and sell call. It’s an approach to make informed decisions while investing in stocks. Stock analysis can be categorised into – fundamental analysis and technical analysis. Fundamental analysis is evaluation of data from sources, including financial records, economic reports, company assets, and market share. Analysts typically study the company’s financial statements – balance sheet, income statement, cash flow statement, and footnotes. These statements are made available to the investors in the form of quarterly earnings, disclosures to stock exchanges in compliance with the Securities and Exchange Board of India (Sebi) norms. In fundamental analysis, the analysts particularly check for a company's core income, income from other sources, profitability, guidance, assets and liabilities and debt ratio among other parameters. The other method, i.e. the technical analysis focuses purely on statistical data. It works on two assumptions; one, the stock price reflects the fundamentals. Second, the study of past and present movement in prices can help determine the future price trends. Technical analysis primarily deals with price, volume, demand and supply factors. This method is effective only when supply and demand forces influence the market. However, when outside factors are involved in a price movement, technical analysis may not be successful. More

    Jump to
    • Super Six chart picks for September 15

      Super Six chart picks for September 15

      Meghana V Malkan of malkansview.com advises buying Glenmark Pharma with a target of Rs 1085.

    • Wockhardt traders pick, may test Rs 1550: Hemant Thukral

      Wockhardt traders pick, may test Rs 1550: Hemant Thukral

      According to Hemant Thukral of Aditya Birla Money, Wockhardt is a good traders pick and feels that it may test Rs 1550.

    • Buy pharma stocks, says Sudarshan Sukhani

      Buy pharma stocks, says Sudarshan Sukhani

      Sudarshan Sukhani of s2analytics.com is of the view that pharmaceutical is an opportunity.

    • Bull's Eye: Buy UPL, Eros, Dish TV, sell Ceat, Sun TV, BEL

      Bull's Eye: Buy UPL, Eros, Dish TV, sell Ceat, Sun TV, BEL

      Manish Sharma of Destimoney Securities advises selling Bharat Electronics with a target of Rs 3150.

    • HDFC Bank, Infosys top picks; like L&T, IOC: R Sreeshankar

      HDFC Bank, Infosys top picks; like L&T, IOC: R Sreeshankar

      According to R Sreesankar, Head - Institutional Equities at Prabhudas Lilladher, HDFC Bank and Infosys are the top picks and likes State Bank of India, ICICI Bank, Larsen & Toubro, Maruti Suzuki India, Tata Motors, IndusInd Bank and Indian Oil Corporation.

    • Top buzzing midcap stocks to trade on September 10

      Top buzzing midcap stocks to trade on September 10

      Here are a few top buzzing midcap stocks picked by CNBC-TV18's analysts in trade today. We have - UPL, Rallis India, Glenmark Pharmaceutical, Torrent Pharmaceutical, Suven Life Sciences, Jindal Steel and Power Limited (JSPL), Uttam Galva, Bhushan Steel, Shree Pushkar Chemicals & Fertilisers & Pennar Engineered Building Systems.

    • Buy Glenmark Pharma, target Rs 1120: Manav Chopra

      Buy Glenmark Pharma, target Rs 1120: Manav Chopra

      Manav Chopra of Networth Stock Broking recommends buying Glenmark Pharma for a target of Rs 1120.

    • Is it the right time to enter pharma stocks?

      Is it the right time to enter pharma stocks?

      The pharma sector has seen the biggest correction over the past one month. The index itself has seen a 5 percent fall from the top. Abhishek Sharma, a pharma analyst at IIFL, gave his views on Dr Reddy's, Glenmark, Cipla and Sun Pharma.

    • Bull's Eye: Sell Wockhardt, Asian Paints, buy SKS Micro

      Bull's Eye: Sell Wockhardt, Asian Paints, buy SKS Micro

      Sharmila Joshi, Market Expert advises buying KS Micro with a target of Rs 450.

    • Glenmark Pharma top pick, says Prakash Diwan

      Glenmark Pharma top pick, says Prakash Diwan

      Prakash Diwan of Altamount Capital Management is of the view that Glenmark Pharma is one of the top picks.

    • Bull's Eye:Sell NMDC, DLF, REC, IRB Infra, Ceat, Amara Raja

      Bull's Eye:Sell NMDC, DLF, REC, IRB Infra, Ceat, Amara Raja

      CA Rudramurthy BV of Vachana Investments advises buying UFO Moviez India with a target of Rs 640.

    • Like Glenmark, Mindtree, Persistent Systems: R Sreesankar

      Like Glenmark, Mindtree, Persistent Systems: R Sreesankar

      R Sreesankar, Head - Institutional Equities at Prabhudas Lilladher likes Glenmark Pharma, Mindtree, Persistent Systems, Jubilant Lifesciences and JK Lakshmi Cement from the midcap space.

    • Buy Glenmark Pharma, advises Sudarshan Sukhani

      Buy Glenmark Pharma, advises Sudarshan Sukhani

      Sudarshan Sukhani of s2analytics.com recommends buying Glenmark Pharma as the stock could embark on a new upmove.

    • Bull's Eye: Buy LIC Housing, Just Dial, JSPL, Canara Bank

      Bull's Eye: Buy LIC Housing, Just Dial, JSPL, Canara Bank

      Dharmesh Kant of India Nivesh Securities is of the view that one may buy LIC Housing Finance with a target of Rs 490.

    • Pharmaceutical stocks buying opportunity: Sudarshan Sukhani

      Pharmaceutical stocks buying opportunity: Sudarshan Sukhani

      Sudarshan Sukhani of s2analytics.com is of the view that pharmaceutical is a buying opportunity.

    • Glenmark Pharma can head higher, target Rs 1253: Rajat Bose

      Glenmark Pharma can head higher, target Rs 1253: Rajat Bose

      Rajat Bose of rajatkbose.com is of the view that Glenmark Pharma is a strong counter as the stock can head higher and test Rs 1253.

    • Buy Lupin, Glenmark Pharma on dips: Sudarshan Sukhani

      Buy Lupin, Glenmark Pharma on dips: Sudarshan Sukhani

      Sudarshan Sukhani of s2analytics.com is of the view that one can buy Lupin and Glenmark Pharma on dips.

    • Like Divis Laboratories, Torrent Pharma: Anmol Ganjoo

      Like Divis Laboratories, Torrent Pharma: Anmol Ganjoo

      Anmol Ganjoo of JM Financial likes Divis Laboratories and Torrent Pharma from the pharma space.

    • Top buzzing midcap stocks to trade on August 19

      Top buzzing midcap stocks to trade on August 19

      Here are a few top buzzing midcap stocks picked by CNBC-TV18's analysts in trade today. We have - Sun Pharma, Rel Comm, Bharti Airtel, Glenmark Pharma, Jaypee Infra, AurionPro Solutions & Majesco.

    • Glenmark Pharma top pick, like Ipca Lab: Sudip Bandopadhyay

      Glenmark Pharma top pick, like Ipca Lab: Sudip Bandopadhyay

      Sudip Bandopadhyay of Destimoney Securities is of the view that Glenmark Pharma is the top pick and likes Ipca Labs and Indoco Remedies.

    • Buy TCS, Glenmark Pharma: Yogesh Mehta

      Buy TCS, Glenmark Pharma: Yogesh Mehta

      Yogesh Mehta of Motilal Oswal recommends buying Tata Consultancy Services and Glenmark Pharma.

    • Buy Glenmark Pharma, target Rs 1200: Chandan Taparia

      Buy Glenmark Pharma, target Rs 1200: Chandan Taparia

      Chandan Taparia of Anand Rathi Securities recommends buying Glenmark Pharma for a target of Rs 1200.

    • Prefer IT, pharma space: Pashupati Advani

      Prefer IT, pharma space: Pashupati Advani

      Pashupati Advani of Globalforay is of the view that one may prefer IT and pharma space.

    • Top buzzing midcap stocks to trade on August 14

      Top buzzing midcap stocks to trade on August 14

      Here are a few top buzzing midcap stocks picked by CNBC-TV18's analysts in trade today. We have – DLF, Glenmark Pharma, India Bull Hsg, JSPL, Sun Pharma, Canara Bank, Bank Of India, Union Bank, Bank Of Baroda & NTPC.

    • Buy Glenmark 1060 Call, bull spread in Britannia: VK Sharma

      Buy Glenmark 1060 Call, bull spread in Britannia: VK Sharma

      VK Sharma of HDFC Securities recommends buying Glenmark Pharma 1060 Call. "I suggest a bull spread in Britannia Industries wherin one can buy 3,400 Call and sell 3500 call.

    Advisory Alert: It has come to our attention that certain individuals are representing themselves as affiliates of Moneycontrol and soliciting funds on the false promise of assured returns on their investments. We wish to reiterate that Moneycontrol does not solicit funds from investors and neither does it promise any assured returns. In case you are approached by anyone making such claims, please write to us at grievanceofficer@nw18.com or call on 02268882347